Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries

BACKGROUND: Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. METHODS: This study included all adult patients who received BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) or combinations BRAF/MEK inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guha, Avirup, Jain, Prantesh, Fradley, Michael G., Lenihan, Daniel, Gutierrez, Jahir M., Jain, Chhavi, de Lima, Marcos, Barnholtz‐Sloan, Jill S., Oliveira, Guilherme H., Dowlati, Afshin, Al‐Kindi, Sadeer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209554/
https://www.ncbi.nlm.nih.gov/pubmed/33982883
http://dx.doi.org/10.1002/cam4.3938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209554/
https://www.ncbi.nlm.nih.gov/pubmed/33982883
http://dx.doi.org/10.1002/cam4.3938

Ejemplares similares